Report Analysis and Forecast on Neuroendocrine Tumors - Pipeline Review, H1 2016
Neuroendocrine Tumors - Pipeline Review, H1 2016 is a new market research publication announced by Reportstack. This report provides an overview of the Neuroendocrine Tumors pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Neuroendocrine Tumors, complete with analysis by stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Neuroendocrine Tumors and features dormant and discontinued projects.
To view the table of contents and know more details please visit Neuroendocrine Tumors - Pipeline Review, H1 2016
This report is built using data and information sourced from a proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. The profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Scope
- The report provides a snapshot of the global therapeutic landscape of Neuroendocrine Tumors
- The report reviews pipeline therapeutics for Neuroendocrine Tumors by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report reviews key players involved Neuroendocrine Tumors therapeutics and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Neuroendocrine Tumors
- The report reviews pipeline therapeutics for Neuroendocrine Tumors by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report reviews key players involved Neuroendocrine Tumors therapeutics and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Neuroendocrine Tumors
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Neuroendocrine Tumors pipeline depth and focus of Indication therapeutics
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Neuroendocrine Tumors pipeline depth and focus of Indication therapeutics
Companies Mentioned
Advanced Accelerator Applications S.A. Aegis Therapeutics, LLC Amgen Inc. AVEO Pharmaceuticals, Inc. Boehringer Ingelheim GmbH Chiasma, Inc. Crinetics Pharmaceuticals, Inc. Daiichi Sankyo Company, Limited Delcath Systems, Inc. DexTech Medical AB Eisai Co., Ltd. Exelixis, Inc. Foresee Pharmaceuticals, LLC Hutchison MediPharma Limited Intezyne, Inc INVENT Pharmaceuticals, Inc. Ipsen S.A. Jiangsu Hengrui Medicine Co., Ltd. Karyopharm Therapeutics, Inc. Lexicon Pharmaceuticals, Inc. Midatech Pharma Plc Millennium Pharmaceuticals, Inc. MolMed S.p.A. Northwest Biotherapeutics, Inc. Novartis AG OctreoPharm Sciences GmbH OXiGENE, Inc. Peptron, Inc. Pfizer Inc. Pharma Mar, S.A. Progenics Pharmaceuticals, Inc. Provectus Biopharmaceuticals, Inc. Sompharmaceuticals S.A. Strongbridge Biopharma plc Vascular Biogenics Ltd.
Contact:
Debora White
Manager - Marketing
Ph: +1-888-789-6604
Reportstack Market Research
###
posted by Reportstack @ 08:10
0 Comments
0 Comments:
Post a Comment
Subscribe to Post Comments [Atom]
<< Home